Combined BRCA2 and MAGEC3 expression predict outcome in Advanced Ovarian Cancers
Authors:
Preprint
Abstract
Like BRCA2, MAGEC3 is an ovarian cancer predisposition gene that has been shown to have prognostic significance in ovarian cancer patients. Despite the clinical significance of each individual gene, no studies have been done to assess the clinical significance of their combined expression. We therefore sought to determine the relationship between MAGEC3 and BRCA2 expression in ovarian cancer and their association with patient characteristics and outcomes. Immuno-histochemical staining was quantitated on tumor microarrays of human tumor samples obtained from 357 patients with epithelial ovarian cancer to ascertain BRCA2 expression levels. In conjunction with our previously published MAGEC3 expression data, we observed a weak inverse correlation of MAGEC3 with BRCA2 expression (r= -0.15; p<0.05) in cases with full-length BRCA2. Patients with optimal cytoreduction, loss of MAGEC3, and detectable BRCA2 expression had better overall (median OS: 127.9 vs 65.3 months, p=0.035) and progression-free (median PFS: 85.3 vs 18.8 months, p=0.002) survival compared to patients that were BRCA2 expressors with MAGEC3 normal levels. Our results suggest that combined expression of MAGEC3 and BRCA2 serves as a better predictor of prognosis than each marker alone. Simple Summary: Early detection of ovarian cancer is a significant clinical challenge, with most women presenting with advanced stages of disease at initial diagnosis. The aim of this study was to evaluate the role of MAGEC3 and BRCA2 in epithelial ovarian cancer progression. We evaluated the effect of MAGEC3 and BRCA2 on the other’s expression. We tested this in humans using immunohistochemical staining of human tumor samples obtained from patients with epithelial ovarian cancer (n = 357). We found a weak inverse correlation between MAGEC3 and BRCA2 expression in epithelial ovarian cancers. Further, our data suggests that the combined expression of MAGEC3 and BRCA2 may be a better predictor of outcomes in patients than the individual markers alone.Keywords
All Related Versions
- Published version: Cancers, 14 (19), 4724.
This publication has 49 references indexed in Scilit:
- BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous CarcinomasAmerican Journal of Surgical Pathology, 2013
- Homologous recombination and its regulationNucleic Acids Research, 2012
- PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and BeyondCurrent Oncology Reports, 2011
- MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin LigasesMolecular Cell, 2010
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break RepairJournal of Clinical Oncology, 2008
- Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2Molecular Cell, 2006
- A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody ProteomicsMolecular & Cellular Proteomics, 2005
- Screening of BRCA1 Mutation Using Immunohistochemical Staining with C‐Terminal and N‐Terminal Antibodies in Familial Ovarian CancersJapanese Journal of Cancer Research, 2000
- THE GENETICS OF BREAST CANCER SUSCEPTIBILITYAnnual Review of Genetics, 1998
- Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13Science, 1994